EcoDrugPlus

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSHBUG00000009285
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSHBUG00000006089
Gene Symbol: F2R
1 Cross references
247 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSHBUG00000008230
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSHBUG00000001471
Gene Symbol: LOC102310783
3 Cross references
78 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSHBUG00000001455
Gene Symbol: LOC102311705
3 Cross references
232 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSHBUG00000001458
Gene Symbol: LOC102311392
3 Cross references
234 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSHBUG00000005494
Gene Symbol: LOC102312281
2 Cross references
211 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSHBUG00000016212
Gene Symbol: CCDC6
3 Cross references
207 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSHBUG00000007537
Gene Symbol: LOC102303990
2 Cross references
252 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSHBUG00000003089
Gene Symbol: CSF1R
4 Cross references
63 Possible Orthologues:

Complement C5-Like

Ensembl ID : ENSHBUG00000022552
Gene Symbol: LOC102310221
2 Cross references
216 Possible Orthologues:

Corticotropin-Releasing Factor Receptor 1-Like

Ensembl ID : ENSHBUG00000003724
Gene Symbol: LOC102308014
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).